## **Core Concept**
The question pertains to the treatment of rheumatoid arthritis (RA) with fully humanized antibodies. Rheumatoid arthritis is a chronic autoimmune disorder that primarily affects joints, leading to inflammation and pain. The treatment often involves disease-modifying antirheumatic drugs (DMARDs), including biologic agents like monoclonal antibodies.

## **Why the Correct Answer is Right**
The correct answer, **Adalimumab**, is a fully humanized monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine involved in the systemic inflammation characteristic of RA. By inhibiting TNF-α, adalimumab reduces inflammation and slows disease progression. It is administered via subcutaneous injection and is a key biologic DMARD used in the treatment of RA.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Although the name is not provided, several monoclonal antibodies are used in RA treatment, but without the name, it's hard to directly refute. Generally, many biologics are effective in RA, but their mechanisms and targets vary.
- **Option B:** Again, lacking a specific name, but if considering other TNF inhibitors like etanercept or infliximab, these are not fully humanized (etanercept is a fusion protein, and infliximab is chimeric).
- **Option C:** Similarly, without a specific name, it's challenging to directly address. However, drugs like rituximab (a chimeric monoclonal antibody against CD20) are used in RA but are not fully humanized.
- **Option D:** This option would be incorrect based on the accuracy of the correct answer being **Adalimumab**.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that fully humanized antibodies offer an advantage over chimeric or humanized antibodies in terms of reduced immunogenicity, which can lead to better long-term efficacy and lower risk of developing antibodies against the therapeutic itself. Adalimumab, being fully human, exemplifies this advantage.

## **Correct Answer:** B. Adalimumab.